Developer docs
API playgroundTry for free, no card

Search company profiles

Nocion Therapeutics

Full company profile

uuid0004gqm

Namestring
Nocion Therapeutics
Legal namestring
Nocion Therapeutics, Inc.
Websiteurl
nociontx.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
chronic cough therapeutics, charged sodium channel blockers, sensory neuron modulators, inhaled dry powder drugs, neurogenic inflammation treatments
Industry2 codes
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Chronic Cough Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Revenue expected from commercialization of taplucainium and other nocion-based therapeutics for chronic cough, pain, itch, and neurogenic inflammation conditions upon regulatory approval.

nociontx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nocion Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary class of small molecule charged sodium channel blockers ("nocions") designed to selectively silence activated sensory neurons that drive chronic cough, pain, itch, and neurogenic inflammation. Its lead product, taplucainium (formerly NTX-1175), is a first-in-class inhaled dry powder formulation currently in Phase 2b development (ASPIRE study) for refractory and unexplained chronic cough. The company is leveraging the same Nocion platform to advance additional pipeline programs in dermatology, pain, gastrointestinal disorders, women's health, oncology, and ocular disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 62% reduction in awake cough frequency observed within 15 minutes after first dose in Phase 2a study
+3 more records
Product overview1 text field

Nocion Therapeutics is a clinical-stage biopharmaceutical company developing a platform of novel small molecule charged sodium channel blockers called 'nocions' that selectively silence activated sensory neurons. The company's lead product is taplucainium (formerly NTX-1175), an inhaled dry powder for chronic cough currently in Phase 2b clinical development. The Nocion platform enables multiple proprietary molecules optimized for different tissues and delivery routes, supporting a pipeline of programs spanning cough, dermatological conditions (NTX-2009), pain, gastrointestinal disorders, women's health, oncology, and ocular diseases.

Product and service2 records
1Taplucainium (formerly NTX-1175)
CategoryInhaled chronic cough therapeutic
Description

First-in-class inhaled dry powder formulation of a charged sodium channel blocker (nocion) designed to selectively silence activated airway nociceptors for the treatment of refractory and unexplained chronic cough in adults. Delivered once daily via dry powder inhaler, with rapid onset of cough reduction within 15 minutes and up to 24 hours of symptom relief.

2Nocion Platform (Nocions™)
CategoryProprietary small molecule drug platform
Description

Proprietary class of small molecule charged sodium channel blockers (CSCBs) designed to selectively silence activated sensory neurons (nociceptors) that drive cough, pain, itch, and neurogenic inflammation. The platform enables multiple molecules optimized for different tissues and delivery routes (inhaled, topical, oral, injection, ocular), supporting Nocion's broader pipeline across dermatology, pain, GI, women's health, oncology, and ocular indications.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Harvard Office of Technology Development
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-04-17
Description

Exclusive license to foundational intellectual property from Harvard University and Boston Children's Hospital. IP developed by founders Bruce Bean, Clifford Woolf, and Bruce Levy at Harvard Medical School and affiliated hospitals.

nociontx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-04-17
Description

Co-licensor of foundational intellectual property with Harvard OTDB. Technology Development Fund supported initial research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Acquired Afferent Pharmaceuticals and developed gefapixant (P2X3 antagonist) for chronic cough. Discontinued U.S. filing but remains a major respiratory incumbent with potential re-entry, posing both competitive and partnership risk.

TypeEmerging player
Description

Develops selective sodium channel blockers (e.g., VX-548 / suzetrigine for acute pain) — closest large-cap analog to Nocion's charged sodium channel blocker approach. Differentiated by indication (pain vs. cough) but mechanistically comparable.

TypeDirect peer
Description

Most direct competitor in refractory chronic cough, developing camlipixant (P2X3 antagonist). Acquired by GSK for ~$2B; same indication, overlapping KOL and clinical operations talent pool (including Joan Shaw, now at Nocion).

TypeBroad incumbent
Description

Late-stage respiratory biopharma (ensifentrine for COPD) with overlapping inhaled-therapeutics expertise and pulmonology-focused commercial footprint. Adjacent rather than direct competitor, but comparable go-to-market motion.

TypeBroad incumbent
Description

Major respiratory franchise (Fasenra, Symbicort, Trixeo) with established pulmonology commercial infrastructure. Potential acquirer/partner for taplucainium given strategic fit with chronic cough and broader respiratory portfolio.

TypeDirect peer
Description

Developed neurokinin-1 receptor antagonists for chronic cough; acquired by GSK in 2020. Direct competitor in the refractory chronic cough space and part of GSK's growing cough franchise.

TypeEmerging player
Description

Clinical-stage biopharma with respiratory and rare disease programs, including work in chronic cough and lung diseases. Similar stage and therapeutic focus, comparable platform-leverage model.

TypeRegional player
Description

Japanese pharma developing P2X3 antagonists (e.g., sivopixant) for chronic cough in Asia. Comparable mechanism and indication, but primarily competing in Japan/Asia rather than U.S./EU.

TypeEmerging player
Description

Inhaled respiratory therapeutics company; Nocion CEO Richard Batycky currently serves on Pulmatrix's board. Closely linked respiratory-focused specialty pharma with overlapping inhaled drug delivery expertise.

10GSK
TypeBroad incumbent
Description

Major respiratory franchise holder post-Bellus Health acquisition, with established commercial reach in pulmonology. Represents both the most likely large-cap acquirer of Nocion and the primary competitive threat to taplucainium.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nocion Therapeutics

Chronic Cough Therapeuticsnociontx.com

Nocion Therapeutics firmographics

Firmographics
Name
Nocion Therapeutics
Legal name
Nocion Therapeutics, Inc.
Website
https://nociontx.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Nocion Therapeutics industry classification

Industry
Product category
Chronic Cough Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals

Keywords

  • Chronic cough therapeutics
  • Charged sodium channel blockers
  • Sensory neuron modulators
  • Inhaled dry powder drugs
  • Neurogenic inflammation treatments

Where Nocion Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Nocion Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company. Revenue expected from commercialization of taplucainium and other nocion-based therapeutics for chronic cough, pain, itch, and neurogenic inflammation conditions upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Nocion Therapeutics product offering

Product offering

Core offering

Nocion Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary class of small molecule charged sodium channel blockers ("nocions") designed to selectively silence activated sensory neurons that drive chronic cough, pain, itch, and neurogenic inflammation. Its lead product, taplucainium (formerly NTX-1175), is a first-in-class inhaled dry powder formulation currently in Phase 2b development (ASPIRE study) for refractory and unexplained chronic cough. The company is leveraging the same Nocion platform to advance additional pipeline programs in dermatology, pain, gastrointestinal disorders, women's health, oncology, and ocular disease.

Product overview

Nocion Therapeutics is a clinical-stage biopharmaceutical company developing a platform of novel small molecule charged sodium channel blockers called 'nocions' that selectively silence activated sensory neurons. The company's lead product is taplucainium (formerly NTX-1175), an inhaled dry powder for chronic cough currently in Phase 2b clinical development. The Nocion platform enables multiple proprietary molecules optimized for different tissues and delivery routes, supporting a pipeline of programs spanning cough, dermatological conditions (NTX-2009), pain, gastrointestinal disorders, women's health, oncology, and ocular diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Taplucainium (formerly NTX-1175) First-in-class inhaled dry powder formulation of a charged sodium channel blocker (nocion) designed to selectively silence activated airway nociceptors for the treatment of refractory and unexplained chronic cough in adults. Delivered once daily via dry powder inhaler, with rapid onset of cough reduction within 15 minutes and up to 24 hours of symptom relief.
  • Nocion Platform (Nocions™) Proprietary class of small molecule charged sodium channel blockers (CSCBs) designed to selectively silence activated sensory neurons (nociceptors) that drive cough, pain, itch, and neurogenic inflammation. The platform enables multiple molecules optimized for different tissues and delivery routes (inhaled, topical, oral, injection, ocular), supporting Nocion's broader pipeline across dermatology, pain, GI, women's health, oncology, and ocular indications.

Quantifiable outcome

  • 62% reduction in awake cough frequency observed within 15 minutes after first dose in Phase 2a study
  • +3 more outcomes

Companies that use Nocion Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Nocion Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Nocion Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Harvard Office of Technology DevelopmentcoreStrategic or Co-development Partner · 17 April 2019Exclusive license to foundational intellectual property from Harvard University and Boston Children's Hospital. IP developed by founders Bruce Bean, Clifford Woolf, and Bruce Levy at Harvard Medical School and affiliated hospitals.
  • Boston Children's HospitalcoreStrategic or Co-development Partner · 17 April 2019Co-licensor of foundational intellectual property with Harvard OTDB. Technology Development Fund supported initial research.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Nocion Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Merck & Co. Acquired Afferent Pharmaceuticals and developed gefapixant (P2X3 antagonist) for chronic cough. Discontinued U.S. filing but remains a major respiratory incumbent with potential re-entry, posing both competitive and partnership risk.
  • Verona Pharma: Late-stage respiratory biopharma (ensifentrine for COPD) with overlapping inhaled-therapeutics expertise and pulmonology-focused commercial footprint. Adjacent rather than direct competitor, but comparable go-to-market motion.
  • AstraZeneca: Major respiratory franchise (Fasenra, Symbicort, Trixeo) with established pulmonology commercial infrastructure. Potential acquirer/partner for taplucainium given strategic fit with chronic cough and broader respiratory portfolio.
  • GSK: Major respiratory franchise holder post-Bellus Health acquisition, with established commercial reach in pulmonology. Represents both the most likely large-cap acquirer of Nocion and the primary competitive threat to taplucainium.

Emerging players

  • Vertex Pharmaceuticals: Develops selective sodium channel blockers (e.g., VX-548 / suzetrigine for acute pain) — closest large-cap analog to Nocion's charged sodium channel blocker approach. Differentiated by indication (pain vs. cough) but mechanistically comparable.
  • Mereo BioPharma: Clinical-stage biopharma with respiratory and rare disease programs, including work in chronic cough and lung diseases. Similar stage and therapeutic focus, comparable platform-leverage model.
  • Pulmatrix: Inhaled respiratory therapeutics company; Nocion CEO Richard Batycky currently serves on Pulmatrix's board. Closely linked respiratory-focused specialty pharma with overlapping inhaled drug delivery expertise.

Direct peers

  • Bellus Health (acquired by GSK): Most direct competitor in refractory chronic cough, developing camlipixant (P2X3 antagonist). Acquired by GSK for ~$2B; same indication, overlapping KOL and clinical operations talent pool (including Joan Shaw, now at Nocion).
  • NeRRe Therapeutics (acquired by GSK): Developed neurokinin-1 receptor antagonists for chronic cough; acquired by GSK in 2020. Direct competitor in the refractory chronic cough space and part of GSK's growing cough franchise.

Regional players

  • Shionogi: Japanese pharma developing P2X3 antagonists (e.g., sivopixant) for chronic cough in Asia. Comparable mechanism and indication, but primarily competing in Japan/Asia rather than U.S./EU.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Nocion Therapeutics social profiles

Digital presence

Nocion Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nocion Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Nocion Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nocion Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nocion Therapeutics

What does Nocion Therapeutics do?

Nocion Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary class of small molecule charged sodium channel blockers ("nocions") designed to selectively silence activated sensory neurons that drive chronic cough, pain, itch, and neurogenic inflammation. Its lead product, taplucainium (formerly NTX-1175), is a first-in-class inhaled dry powder formulation currently in Phase 2b development (ASPIRE study) for refractory and unexplained chronic cough. The company is leveraging the same Nocion platform to advance additional pipeline programs in dermatology, pain, gastrointestinal disorders, women's health, oncology, and ocular disease.

Is Nocion Therapeutics a public or private company?

Nocion Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nocion Therapeutics founded?

Nocion Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Nocion Therapeutics based?

Nocion Therapeutics is headquartered in Watertown, United States, in the North America region.

How does Nocion Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Nocion Therapeutics's main competitors?

Broad incumbents on record are Merck & Co., Verona Pharma, AstraZeneca and GSK. Emerging players are Vertex Pharmaceuticals, Mereo BioPharma and Pulmatrix. Direct peers are Bellus Health (acquired by GSK) and NeRRe Therapeutics (acquired by GSK). Shionogi is listed as a regional player.

Does Nocion Therapeutics have an API?

No public API is recorded for Nocion Therapeutics.

What industry is Nocion Therapeutics in?

Nocion Therapeutics's product category is Chronic Cough Therapeutics. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals, with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceNocion Therapeutics Appoints Vineet Agarwal as Chief Business OfficerNocion Therapeutics appointed Vineet Agarwal as Chief Business Officer, bringing nearly two decades of biotech leadership experience. He previously served as CFO at Korro Bio, which raised over $350 million. The company is approaching topline data from its Phase 2b ASPIRE study on taplucainium for chronic cough.Business Wire BlogNocion Therapeutics Appoints Vineet Agarwal as Chief Business OfficerNocion Therapeutics appointed Vineet Agarwal as Chief Business Officer. He brings over two decades of biotech experience, including CFO roles at Korro Bio and J.P. Morgan. The company is approaching topline data from its Phase 2b ASPIRE study for chronic cough.Clinical Trials ArenaNocion completes patient enrolment in Phase IIb ASPIRE trialNocion Therapeutics completed enrolment in its Phase IIb ASPIRE trial for taplucainium in chronic cough, enrolling 240 patients across 100+ sites. The trial will assess safety, tolerability, and efficacy over one month, with topline data expected in Q3 2026.BioSpaceNocion Therapeutics Strengthens Board of Directors with Appointment of Mark IwickiNocion Therapeutics announced the expansion of its Board of Directors with the appointment of Mark Iwicki, a biotechnology industry veteran with over three decades of leadership experience spanning R&D, product development, and corporate strategy. Iwicki currently serves as CEO of Inhibikase Therapeutics and brings prior experience leading companies through strategic acquisitions, including Civitas Therapeutics' acquisition by Acorda Therapeutics. The appointment is intended to help advance Nocion's Phase 2b ASPIRE study for taplucainium in refractory or unexplained chronic cough, with top-line data expected mid-year.SecSEC FORM DNocion Therapeutics, Inc. filed a Form D notice with the SEC on March 5, 2026, for an exempt offering of equity securities under Rule 506(b), with a first sale recorded on December 15, 2025. The company, a Delaware corporation headquartered in Watertown, Massachusetts, raised $22,999,999 USD from 13 investors with no minimum investment requirement and no sales commissions or finder's fees.Pulse 2.0Nocion Therapeutics: $93 Million Series B Closed To Advance Taplucainium Toward Late-Stage Development In Chronic CoughNocion Therapeutics has raised a total of $93 million in its Series B financing to support the advancement of taplucainium, an investigational therapy for chronic cough. The funding will extend the company's operating runway through 2027 and supports the ASPIRE Phase 2b clinical trial, with topline results expected in mid-2026. The company aims to address a significant unmet need in the treatment of chronic cough, which affects approximately 27 million U.S. adults.VentureRadarNew Funding Rounds in EczemaThe article lists multiple venture funding rounds for various biotechnology and healthcare companies, including Nocion Therapeutics raising $93 million and Evommune securing $115 million. These investments support the development of novel treatments for conditions such as chronic cough, eczema, and autoimmune diseases. The content aggregates news from sources like Biospace, PR Newswire, and Finsmes.FinSMEsNocion Therapeutics Extends Series B Financing to $93MNocion Therapeutics extended its Series B financing by $23 million, bringing the total raised in this round to $93 million. The Watertown, MA-based biopharmaceutical company will use the funds to advance development of taplucainium dry powder for inhalation for chronic cough treatment beyond the ongoing ASPIRE study toward later-stage activities including an End-of-Phase 2 meeting and CMC activities for clinical development preparation.citybizNocion Therapeutics Extends Series B Financing To $93 MillionNocion Therapeutics announced a $23 million extension to its Series B financing, bringing the total to $93 million, with participation from existing investors including Arkin Bio Capital. The funding extends the company's operating runway through 2027 and will support later-stage development of taplucainium dry powder for chronic cough treatment, including preparations for an End-of-Phase 2 meeting and CMC activities. The ASPIRE Phase 2b clinical trial of taplucainium in adults with refractory or unexplained chronic cough is currently enrolling at sites across the U.S., Canada, the U.K., and Europe, with topline results expected in mid-2026.PharmiWeb.comNocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic CoughNocion Therapeutics has raised $23 million from existing investors in a Series B extension, bringing the total Series B financing to $93 million, with proceeds extending the company's operating runway through 2027. The funding will support late-stage development of taplucainium dry powder for inhalation beyond the ongoing ASPIRE Phase 2b clinical trial in refractory or unexplained chronic cough, with topline results expected in mid-2026. The Series B extension was led by Arkin Bio Capital and Monograph Capital, with participation from nine additional investors including BioInnovation Capital, Canaan Partners, and F-Prime Capital.